1. Enzymes involved in trehalose-chitin synthesis in Haemonchus contortus could be vaccine candidates for goats.
- Author
-
Wen Z, Amu J, Aimulajiang K, Feng J, Chen C, Xu Y, Lu M, Xu L, Song X, Li X, and Yan R
- Subjects
- Animals, Chitin, Vaccines immunology, Recombinant Proteins immunology, Recombinant Proteins genetics, Larva immunology, Female, Adjuvants, Immunologic administration & dosage, Helminth Proteins immunology, Helminth Proteins genetics, Helminth Proteins metabolism, Quillaja Saponins, Haemonchus immunology, Goats, Haemonchiasis veterinary, Haemonchiasis prevention & control, Haemonchiasis parasitology, Goat Diseases prevention & control, Goat Diseases parasitology, Goat Diseases immunology, Phosphoric Monoester Hydrolases metabolism, Phosphoric Monoester Hydrolases immunology, Phosphoric Monoester Hydrolases genetics, Antibodies, Helminth, Trehalose, Glucosyltransferases immunology, Glucosyltransferases metabolism, Glucosyltransferases genetics
- Abstract
Background: Trehalose-6-phosphate synthase (HcTPS) and trehalose-6-phosphate phosphatase (HcGOB) are key enzymes for trehalose synthesis in Haemonchus contortus. In addition, previous studies have also demonstrated that HcTPS and HcGOB can regulate the function of host immune cells in vitro, and are important immunosuppressive molecules. Therefore, this study evaluated the potential of HcTPS and HcGOB as vaccine candidates through in vitro and in vivo experiments., Methods: To evaluate the inhibitory effects of polyclonal antibodies on egg hatching and larval development, anti-rHcTPS and anti-rHcGOB antibodies were incubated separately with eggs and first-stage larvae (L1s) under controlled in vitro conditions. For immunization studies, recombinant proteins (rHcTPS and rHcGOB) were formulated with Quil-A adjuvant, and administered to goats through subcutaneous injection. Vaccine efficacy against Haemonchus contortus infection was determined through comprehensive analysis of multiple parasitological parameters, including: (1) egg abnormality rate, (2) hatching success rate, (3) reduction egg output rates, and (4) reduction in adult worm burden., Results: The results of in vitro experiments showed that polyclonal antibodies against HcTPS and HcGOB had no effect on the hatching rate of eggs, but significantly affected the development from L1s to infectious third stage larvae (L3s). After immunization with recombinant HcTPS protein (rHcTPS) and recombinant HcGOB protein (rHcGOB), high levels of antigen-specific immunoglobulin G (IgG) were produced in goats, and remained till the end of the experiment. Compared with the Quil-A adjuvant control group, the number of deformed eggs in the rHcTPS protein- immunized group and the rHcGOB protein- immunized group were significantly increased. In the rHcTPS protein-immunized group and the rHcGOB protein-immunized group, the deformity rate of eggs was 9.59% and 17.30%, respectively, and the hatching rate of eggs was reduced by 11.27% and 13.71%, respectively. Moreover, compared with the Quil-A adjuvant control group, the number of eggs and adults in the HcTPS protein- immunized group decreased by 64.47% and 60.93%, respectively, and the number of eggs and adults in the rHcGOB protein- immunized group decreased by 63.97% and 69.54%, respectively. Furthermore, compared with the control group (Quil-A adjuvant), the trehalose content in the rHcTPS protein- immunized group and the rHcGOB protein- immunized group was also significantly reduced., Conclusions: These findings indicate that rHcTPS and rHcGOB exhibit superior immune protective effects, rendering them promising candidates for vaccine development., Competing Interests: Declarations. Ethics approval and consent to participate: All protocols were approved by the Science and Technology Agency of Jiangsu Province [SYXK (SU) 2010-0005]. All animal studies were carried out in compliance with the Guidelines of the Animal Welfare Board of Nanjing Agricultural University, China. The daily health conditions of the animals were monitored throughout the experiments. Competing interests: The authors declare no competing interests. Consent for publication: All authors provide this consent., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF